|
HS Code |
618632 |
| Product Name | HIFULL HL-380 Colloidal Silica (Pharma Grade) |
| Appearance | Milky white liquid |
| Silica Content Wt Percent | 38% |
| Ph Value | 9.0-10.5 |
| Particle Size Nm | 8-15 |
| Density G Per Cm3 | 1.28-1.32 |
| Stabilizer | Sodium |
| Viscosity Cps 25c | <10 |
| Sodium Oxide Na2o Wt Percent | 0.28-0.38% |
| Chloride Content Wt Percent | <0.02% |
| Application | Pharmaceutical excipients and processing aids |
| Storage Temperature | 5-35°C |
As an accredited HIFULL HL-380 Colloidal Silica (Pharma Grade) factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | HIFULL HL-380 Colloidal Silica (Pharma Grade) is packaged in 25 kg high-density polyethylene drums, featuring tamper-evident seals. |
| Container Loading (20′ FCL) | Container Loading (20′ FCL) for HIFULL HL-380 Colloidal Silica (Pharma Grade): 80 x 25 kg drums, total 2,000 kg. |
| Shipping | **Shipping for HIFULL HL-380 Colloidal Silica (Pharma Grade):** The product is securely packaged in high-density polyethylene (HDPE) drums or IBC totes to prevent contamination and ensure safety during transit. Temperature-sensitive; avoid freezing and direct sunlight. Includes UN-approved labeling and documentation for international and domestic shipment. Handle as chemical cargo according to MSDS guidelines. |
| Storage | **HIFULL HL-380 Colloidal Silica (Pharma Grade)** should be stored in tightly sealed original containers in a cool, dry, and well-ventilated area. Protect from freezing, direct sunlight, and contamination. Avoid extreme temperatures and ensure containers are kept upright to prevent leakage. Store away from incompatible materials, such as strong acids or bases, to maintain product quality and stability. |
| Shelf Life | HIFULL HL-380 Colloidal Silica (Pharma Grade) has a shelf life of 12 months when stored in tightly sealed original containers. |
Applications of HIFULL HL-380 Colloidal Silica (Pharma Grade) in Industrial ManufacturingAs the original producer of HIFULL HL-380 Colloidal Silica (Pharma Grade), we supply a high-purity, finely controlled colloidal silica tailor-made for regulated pharmaceutical and food-contact applications. Below we detail key industrial downstream sectors and how HL-380 integrates into their manufacturing operations. 1. Tablet Coating and Film-Forming in Solid Dosage PharmaceuticalsPharmaceutical companies use HL-380 as a core excipient for tablet coating and film-forming processes. Its particle uniformity improves mechanical coating strength, enhances moisture barriers, and prevents sticking during high-speed tablet production. Operators disperse the silica into aqueous or hydroalcoholic coating solutions before pan or fluidized bed application, complying with stringent cGMP protocols to ensure batch-to-batch consistency. Customizable incorporation levels allow precise control over film thickness and disintegration profiles in solid oral dosage forms designed for regulated markets. Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
2. Binder and Rheology Modifier in Injectable Lyophilized FormulationsBiopharmaceutical producers rely on highly pure colloidal silica as a binder and rheology modifier during aseptic preparation of injectable drug products, particularly for lyophilized (freeze-dried) vials. Incorporation in pre-lyophilization mixtures stabilizes suspension viscosity and ensures uniform API distribution within each dose, critical for consistent dosage delivery. The high surface area and bioinert profile of HL-380 make it compatible with monoclonal antibody and vaccine platforms, where non-reactivity and lot-to-lot homogeneity cannot be compromised under GMP oversight. Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
3. Clarifying Agent in Bioprocess PurificationHL-380 is introduced by bioprocess engineers as a clarifying and filtration aid for high-value biological fluids, including fermentation-derived enzymes and plasma-derived therapeutics. Its finely sized particles promote rapid aggregation of micron-scale particulate and proteinaceous material, enhancing downstream filter throughput and reducing membrane fouling. Operations adopt HL-380 in depth-filtration steps under validated, cGMP-compliant cleaning and disposal practices governing contact with medicinal intermediates. Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
4. Process Aid for Food-Contact Catalysts and Chromatography MediaLeading manufacturers of food and pharmaceutical-grade catalysts, as well as chromatography media, integrate HL-380 as a structure-controlling aid and inert filler. It creates precisely controlled pore structures in silica-based catalyst bodies and optimizes flow hydrodynamics within chromatography packing materials. Its consistent sub-micron size supports uniform column performance and reproducible separation properties. Regulatory traceability is accompanied by strict adherence to food-contact and compendial purity limits throughout catalyst or adsorbent production runs. Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
5. Flow Agent in Direct Compression NutraceuticalsProducers of dietary supplement and nutraceutical tablets leverage HL-380 for its flow conditioning properties in direct compression blends. Its highly dispersible particles coat active and filler surfaces, minimizing static charge and bridging within feeders or tableting presses. HL-380 thus enables continuous production lines with challenging plant extracts and complex active materials, achieving consistent compression force and uniform tab weight under SQF and ISO-controlled food supplement regulations. Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
|
Competitive HIFULL HL-380 Colloidal Silica (Pharma Grade) prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Making pharmaceutical ingredients that meet strict purity standards isn’t just what we do—it’s what we’ve built our working lives around. HIFULL HL-380 Colloidal Silica emerged from our lab benches and production floors after years of learning what our clients truly need: reliable excipients that perform predictably at every stage. Every container of HL-380 represents our drive for cleaner processing and transparent sourcing. Our team works with regulated, quality-controlled raw inputs and scrutinizes each batch through careful, hands-on testing.
HL-380 stands out because we committed early on to specialized processing. We don’t simply repackage industrial colloidal silicas. We source high-grade silicic acid solutions, apply spray-drying methods built for pharmaceutical use, and maintain a plant environment where outside contaminants remain controlled. Consistency run after run became our baseline goal. HL-380 maintains a narrow particle size distribution—centered reliably between 11 to 30 nanometers—because we fine-tune synthesis parameters with purpose. At the end, the resulting powder holds a low bioburden, leaving minimum residue and avoiding the unpredictability that undermines formula performance in tablets, capsules, and suspensions.
Many colloidal silica powders bring a range of particle sizes, but that variation plays havoc with dissolution, compaction, and flow in actual production. HL-380 benefits from a tightly set range through constant feedback from our mixing and reaction lines. We monitor viscosity and sol stability with every batch, using well-tested laboratory checks—no quick shortcuts, no rushed drying. We also steer clear of byproduct build-up by refining pH control and cleaning procedures in our reactors. This commitment makes HL-380 friendly for pharmaceutical finishing, where customers face tough targets for blend repeatability and dissolution.
Achieving pharmaceutical grade standards starts with careful choices, not just at the main process steps, but with every ancillary input: from water purification to vessel cleaning agents to airtight bagging. All these choices are backed by traceable records—each input and action logged, every result double-checked. Our team insists on hands-on checks, reviewing all materials entering our processing lines. HL-380 undergoes microbial checks, heavy metal panels, and solvency assessments. If a measurement doesn’t meet the specification, the lot is held. Our traceability tracks all movement through the plant and makes matching final product analytics with production records straightforward for every shipment we send.
Pharmaceutical manufacturers face production metrics far removed from other industries. They require fillers and flow aids that stay inert while delivering benchmark performance—no surprises mid-process. HL-380’s hydrophilic nature supports rapid wetting and avoids agglomeration in most blends. Our partners in tablet manufacturing value HL-380 for its performance as a glidant, specifically where micro-sized flow agents would otherwise clump or introduce non-inert chemicals. In liquid and semi-solid pharmaceutical suspension manufacturing, HL-380 resists settling and supports uniform viscosity, saving time at later production steps and improving the shelf stability of finished products.
We see HL-380 put through rigorous pharmaceutical granulation and tableting routines, where granule flow and breakdown characteristics often limit throughput. Our clients report improved batch-to-batch reproducibility because HL-380 leaves no sticky residue on machinery and doesn’t clog fine mesh screens. The powder’s tight particle control cuts down on blend segregation, which matters especially in continuous direct compression operations. These aren’t just lab observations—they come straight from our technical service visits and years of feedback from pharmaceutical partners.
Colloidal silica appears in numerous forms, but not all make the grade for pharmaceuticals. Commodity-grade varieties seldom match HL-380’s trace impurity totals, bulk density, or the level of microbial control demanded in regulated systems. At our facility, product contact surfaces remain fully segregated by product type. We avoid raw materials with unproven certificates of analysis and do not dilute our process flows with off-specification intermediates. HL-380 is never blended with lower grade stocks or repackaged material. This sets its core purity and process reliability apart from re-compounded packs or batches with less-transparent origins.
A clear difference lies in the tails of the particle size distribution. Where commodity silicas present wide distribution curves, HL-380’s range stays sharply defined. This sharply reduces process variation in real-world compaction, capping, or even capsule fill applications by minimizing sieve breakage and powder hold-up. Our controls mean HL-380 doesn’t introduce unexpected ion leaching or add trace metal residues, which can otherwise trigger regulatory investigations or lead to batch failures.
Working with multinational solid-dose pharmaceutical manufacturers who design highly sensitive active formulations gives us insights beyond basic powder handling. HL-380 succeeds with direct compression of formulations containing poorly compressible APIs. Users tell us HL-380 acts as a bridging agent, allowing lower compression forces and achieving consistent tablet hardness without raising the risk of brittle failure or friability. Our team continues visiting customer plants to see the results firsthand: tablets that hold firm during coating and shipment, even with minimal binder content in dry blends.
In suspension-type cough syrups and antacids, HL-380 disperses rapidly with minimum sedimentation. Due to strict surface charge and particle control, visual clarity and mouthfeel remain unimpaired, helping producers boost shelf-life claims and meet appearance standards. This only happens when particle purity remains high—there’s no room for iron, aluminum, or residual detergent. Our in-process checks catch all unwanted variables before each drum leaves our plant.
HL-380 consistently retains its hydrophilicity and dispersibility, even after extended storage in warehouse or distribution conditions. This performance owes a lot to the way we handle bagging, air-purging, and drum-sealing on the packaging line. Moisture gain and surface charge drift—common with inadequately stabilized silica—don’t show up in HL-380’s warehouse lots. Clients regularly retest aged drums and find no measurable deviation from original dispersion specs or pH values. HL-380 aligns well with a wide range of organic actives, binders, and other excipients typically used in tablet blends, oral suspensions, and topical gels.
We watch our long-term stability figures because small batch failures create production headaches that cost more in the long run than any periodic batch saving. HL-380’s role isn’t just technical—it reduces uncertainty in manufacturing, which translates straight to reliable deadlines and more predictable registration filings for our clients.
Scaling up HL-380 wasn’t just about making more powder. Pharmaceutical regulators around the world demand rigorous documentation, from ingredient verification to batch analytics. We have tuned our workflow to make documentation traceable for every supply chain audit. HL-380’s production record can be accessed in real time, and we provide the underlying data packages for our pharmaceutical customers working with health authorities. Ingredient registrations depend on predictability, so our lot certificates are built using both our in-house results as well as third-party confirmatory labs on request. We understand the scrutiny well—our facility runs mock audits and our team engages directly with client QA and RA teams during validation and launch.
HL-380 exceeds required compendial standards for colloidal silica as described in the main pharmacopoeias, through verified control of heat-stable and acid-soluble impurities, loss on ignition, and overall solubility. These controls reassure our partners who operate in regulated and highly competitive global markets.
We take source management, energy optimization, and emissions seriously for HL-380. All utility water drawn for our processes meets or exceeds pharmaceutical ingredient standards and receives additional in-line filtration. Our handling procedures keep ambient dust levels low. Waste silica solids never leave our facility untreated; instead, they travel through approved routes for reprocessing or certified disposal. HL-380’s manufacturing footprint stays minimized through continual process audits aimed at reducing overall water and energy consumption. We keep these benchmarks transparent so clients are informed about the environmental responsibility built into each batch.
HL-380’s chemical profile means it doesn’t release hazardous gases or pose special transport challenges. Every drum ships sealed, batch-labeled, and accompanied by full material compliance data. We support safer plant environments by offering low-dust packs and training partners on best storage and handling practices. Every change to handling, labeling, or minor formula adjustment runs through our product stewardship review, so any risk is flagged and managed internally before external release.
What makes HL-380 work in so many pharmaceutical plants is more than just its physical metrics. Our team believes in fast communication—skipping market jargon in favor of practical, on-site answers. We have supported trouble-shooting on early development lots, reformulations, line transfers, and international launches, ensuring the HL-380 spec keeps up with regulatory shifts and new excipient guidelines. Our support doesn’t stop at delivery. We assist with plant training, process transfer documentation, and technical seminars focused on colloidal silica’s functional mechanisms.
If any issue emerges during blending, tableting, or analytical testing, our in-house experts respond with both data and real-life manufacturing experience. We keep an archive of technical notes, process fix suggestions, and compatibility tips to help customers stay ahead of recurring challenges. Every batch query, deviation, or out-of-spec event traces back to our internal logs, drawing from thousands of previous runs. This collective experience grows every year, directly shaping adjustments and upgrades to HL-380.
Manufacturing HL-380 amid rising regulatory barriers and complex customer requirements took us beyond simple process flowcharts. It’s a result of refining each operational stage—ingredient blending, pH adjustment, particle drying, and drum filling—through a manufacturing lens where end use matters more than theoretical yield. Pharmaceutical demand keeps rising for excipients that can stand up to global transport, variable storage, and increasingly potent actives. HL-380 adapts to this climate by holding purity, consistency, and chemical inertness with each cycle.
Formulation scientists, production supervisors, and QA teams share a common goal: deliver finished drugs on schedule and within spec. HL-380’s consistent performance allows for fewer reworks in the blend room or on the compression line. Our plant team remains open to feedback, whether it concerns downstream blend behavior, new analytical methods, or unexpected granular issues. Every real-world observation feeds straight back to our R&D and process improvement cycles. These direct adjustments drive the ongoing evolution of HL-380, keeping our product relevant no matter how the pharmaceutical landscape shifts.
We continue investing in the future of HL-380 by increasing traceability, automating critical process controls, and upgrading environmental safeguards in our facility. The evolution of pharmaceutical manufacturing keeps raising the bar for excipient purity. HL-380 takes its place not through short-lived technical tricks, but through practical, observable reliability that our clients confirm through their own manufacturing outcomes. We believe in putting effort where it’s visible and useful: better raw material screening, faster problem-solving, and ongoing process education. HL-380 fits within an ecosystem of trust, forged through repeated proof across thousands of pharmaceutical batches and an equal number of unannounced inspections.
As regulatory standards climb and active agent complexity increases, we see HL-380 forming part of the backbone of safe, stable pharmaceutical manufacturing. The product reflects our accumulated knowledge as a manufacturer—and our willingness to keep evolving for those who trust us with the success of their own production.
